All In Biotech

Drug Trial Radar · NCT01093534

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.

Last checked: Nov 20, 2026Latest source record: Dec 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 547 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

547

Actual

Start

Jan 19, 2010

Primary completion

Jun 23, 2011

Study completion Jun 23, 2011

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Mar 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.

Conditions

  • Detrusor Overactivity
  • Overactive Bladder

Interventions

  • PlaceboDrug

    Matching solifenacin placebo tablet

  • solifenacinDrug

    Tablet for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in Bladder Wall ThicknessTime frame: Baseline and Week 12
  2. Neutralized Urinary Nerve Growth Factor Normalized by Urine Creatinine at Week 12Time frame: Week 12

Locations

79 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    West Reading, Pennsylvania

  • Site not named

    Graz, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Edegem, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Kortrijk, Belgium

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Varba, Bulgaria

  • Site not named

    Victoria, British Columbia, Canada

  • Site not named

    Victoria, British Columbia, Canada

  • Site not named

    Barrie, Ontario, Canada

  • Site not named

    Brampton, Ontario, Canada

  • Site not named

    Brantford, Ontario, Canada

  • Site not named

    Kitchener, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Sherbrooke, Quebec, Canada

  • Site not named

    Brno, Czechia

  • Site not named

    Hradec Králové, Czechia

  • Site not named

    Podolí, Czechia

  • Site not named

    Marseille, France

  • Site not named

    Paris, France

  • Site not named

    Aachen, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Hanover, Germany

  • Site not named

    Munich, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Szeged, Hungary

  • Site not named

    Székesfehérvár, Hungary

  • Site not named

    Haifa, Israel

  • Site not named

    Petah Tikva, Israel

  • Site not named

    Ramat Gan, Israel

  • Site not named

    Avellino, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Rome, Italy

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.